Compared with traditional prognostic factors such as tumor size, lymph nodes, estrogen receptor (ER), and progesterone receptor (PR), molecular prognostic biomarkers show an obvious advantage in guiding clinical decision-making for managing breast cancer patients [2]. This evidence concerns the gene ESR1 and breast carcinoma.